Fennec Pharmaceuticals Inc.FENCNASDAQ
Loading
FENC Revenue Growth (YoY Quarterly)•+78.69%
Stock Alarm Pro
Growth Metrics
Latest: Q3 2025vs Q2 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+78.69%
+45.8pp
+110.11%
+79.6pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+1.89%
+0.5pp
+1.89%
+0.5pp
+0.00%
+0.0pp
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +7.05% | -20.78% | -65.52% | +32.91% | +78.69% |
| Gross Profit Growth | -9.17% | -21.98% | -66.25% | +30.52% | +110.11% |
| EBITDA Growth | +0.00% | +0.00% | -105.36% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | -105.88% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | -109.08% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | -108.98% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | -110.29% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +3.45% | +2.34% | +1.97% | +1.34% | +1.89% |
| Weighted Average Shares Diluted Growth | +3.45% | +2.34% | -11.30% | +1.34% | +1.89% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | -111.06% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | -111.06% | +0.00% | +0.00% |
| Receivables Growth | +185.26% | +46.18% | +50.36% | +42.15% | +49.71% |
| Inventory Growth | -35.90% | -50.83% | -31.98% | +2.66% | +119.96% |
| Asset Growth | +209.65% | +67.31% | -32.94% | -28.95% | -16.48% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +25.07% | -37.52% | -38.31% | -39.08% | -43.66% |
| R&D Expense Growth | +708.33% | +52.05% | +3033.33% | -31.85% | -70.10% |
| SG&A Expenses Growth | +49.14% | -26.90% | -17.95% | -1.96% | +11.57% |
1 / 4